What is claimed is:

1. A polypeptide comprising at least one VHH domain that binds FcRn, wherein at least one VHH domain that binds FcRn comprises a CDR1 sequence selected from SEQ ID NOs: 80-81, a CDR2 sequence selected from SEQ ID NOs: 83-84, and a CDR3 sequence of SEQ ID NO: 85.

2. The polypeptide of claim 1, wherein each VHH domain that binds FcRn comprises, independently, a CDR1 sequence selected from SEQ ID NOs: 80-81, a CDR2 sequence selected from SEQ ID NOs: 83-84, and a CDR3 sequence of SEQ ID NO: 85.

3. The polypeptide of claim 1 or claim 2, wherein at least one or each VHH domain that binds FcRn comprises CDR1, CDR2, and CDR3 sequences selected from: SEQ ID NOs: 80, 83, and 85, SEQ ID NOs: 81, 83, and 85; and SEQ ID NOs: 81, 84, and 85.

4. The polypeptide of any one of claims 1-3, wherein at least one or each VHH domain that binds FcRn is humanized.

5. The polypeptide of any one of claims 1-4, wherein at least one or each VHH domain that binds FcRn comprises a sequence at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence selected from SEQ ID NOs: 86-93.

6. The polypeptide of any one of claims 1-5, wherein at least one or each VHH domain that binds FcRn comprises a sequence selected from SEQ ID NOs: 86-93.

7. The polypeptide of any one of claims 1-6, wherein at least one or each VHH domain that binds FcRn binds human FcRn with an affinity of less than 5 nM, less than 2 nM, less than 1 nM, or less than 0.5 nM.

8. The polypeptide of any one of claims 1-7, wherein at least one or each VHH domain that binds FcRn binds human FcRn at pH 6 and at pH 7.4.

9. The polypeptide of any one of claims 1-8, wherein at least one or each VHH domain that binds FcRn blocks binding of human IgG to human FcRn.

10. The polypeptide of any one of claims 1-9, wherein the polypeptide comprises at least one VHH domain that binds albumin.

11. The polypeptide of claim 10, wherein at least one or each VHH domain that binds albumin comprises a CDR1 sequence selected from SEQ ID NOs: 5-8, a CDR2 sequence selected from SEQ ID NOs: 9-21, and a CDR3 sequence of SEQ ID NO: 22.

12. The polypeptide of claim 10 or claim 11, wherein at least one or each VHH domain that binds albumin comprises CDR1, CDR2, and CDR3 sequences selected from: SEQ ID NOs: 5, 9, and 22; SEQ ID NOs: 5, 10, and 22; SEQ ID NOs: 5, 11, and 22; SEQ ID NOs: 5, 12, and 22; SEQ ID NOs: 5, 13, and 22; SEQ ID NOs: 5, 14, and 22; SEQ ID NOs: 5, 15, and

22; SEQ ID NOs: 6, 15, and 22; SEQ ID NOs: 7, 15, and 22; SEQ ID NOs: 8, 15, and 22; SEQ ID NOs: 6, 16, and 22; SEQ ID NOs: 6, 17, and 22; SEQ ID NOs: 6, 18, and 22; SEQ ID NOs: 6, 19, and 22; SEQ ID NOs: 6, 20, and 22; and SEQ ID NOs: 6, 21, and 22.

13. The polypeptide of any one of claims 10-12, wherein at least one or each VHH domain that binds albumin is humanized.

14. The polypeptide of any one of claims 10-13, wherein at least one or each VHH domain that binds albumin comprises a sequence at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence selected from SEQ ID NOs: 23-43 and 97-100.

15. The polypeptide of any one of claims 10-14, wherein at least one or each VHH domain that binds albumin comprises a sequence selected from SEQ ID NOs: 23-43 and 97-100.

16. The polypeptide of any one of claims 10-15, wherein the polypeptide comprises a sequence at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 69-77 or wherein the polypeptide comprises a sequence selected from SEQ ID NOs: 69-77.

17. The polypeptide of any one of claims 10-16, wherein at least one or each VHH domain that binds albumin binds human albumin and at least one albumin selected from cynomolgus monkey, mouse, and rat albumin.

18. The polypeptide of any one of claims 10-16, wherein at least one or each VHH domain that binds albumin binds human, cynomolgus monkey, mouse, and rat albumin.

19. The polypeptide of any one of claims 10-18, wherein:

(a) at least one or each VHH domain that binds albumin binds human albumin with an affinity of less than 5 nM, less than 2 nM, less than 1 nM, or less than 0.5 nM and/or

(b) at least one or each VHH domain that binds albumin binds each of human, cynomolgus monkey, mouse, and rat albumin with an affinity of less than 5 nM, less than 2 nM, less than 1 nM, or less than 0.5 nM and/or

(c) each VHH domain that binds albumin binds human albumin with an affinity of less than 5 nM, less than 2 nM, less than 1 nM, or less than 0.5 nM and/or

(d) each VHH domain that binds albumin binds each of human, cynomolgus monkey, mouse, and rat albumin with an affinity of less than 5 nM, less than 2 nM, less than 1 nM, or less than 0.5 nM.

20. The polypeptide of any one of claims 10-19, wherein at least one or each VHH domain that binds albumin does not bind albumin domain 3 and/or wherein each VHH domain that binds albumin does not interfere with binding of albumin to FcRn.

21. The polypeptide of any one of claims 1-20, wherein the polypeptide comprises at least two, at least three, or at least four VHH domains that bind FcRn and at least one VHH domain that binds albumin, or wherein the polypeptide comprises two, three, or four VHH domains that bind FcRn and one VHH domain that binds albumin.

22. The polypeptide of any one of claims 1-21, wherein the polypeptide comprises at least one binding domain that binds a protein other than albumin or FcRn, wherein

a) at least one binding domain that binds a protein other than albumin or FcRn is a VHH, and/or

b) at least one binding domain that binds a protein other than albumin or FcRn comprises a heavy chain variable region and a light chain variable region.

23. The polypeptide of any one of claims 1-22, each binding domain that binds a protein other than albumin or FcRn is a VHH or each binding domain that binds a protein other than albumin or FcRn comprises a heavy chain variable region and a light chain variable region.

24. The polypeptide of claim 22 or 23, wherein at least one or each binding domain that binds a protein other than albumin or FcRn is a binding domain of a therapeutic antibody, wherein the therapeutic antibody is useful for treating a disease or disorder selected from an autoimmune disease or disorder, an inflammatory disease or disorder, an infection, and cancer.

25. The polypeptide of any one of claims 1-24, wherein the polypeptide comprises an amino acid sequence of a therapeutic protein, wherein the therapeutic protein is useful for treating a disease or disorder selected from an autoimmune disease or disorder, an inflammatory disease or disorder, an infection, and cancer.

26. The polypeptide of any one of claims 1-25, wherein the half-life of the polypeptide is greater than the half-life of the same polypeptide lacking a VHH domain that binds albumin.

27. A pharmaceutical composition comprising the polypeptide of any one of claims 1-26 and a pharmaceutically acceptable carrier.

28. An isolated nucleic acid that encodes the polypeptide of any one of claims 1-26.

29. A vector comprising the nucleic acid of claim 28.

30. A host cell comprising the nucleic acid of claim 28 or the vector of claim 29.

31. A host cell that expresses the polypeptide of any one of claims 1-26.

32. A method of producing the polypeptide of any one of claims 1-26, comprising incubating the host cell of claim 30 or claim 31 under conditions suitable for expression of the polypeptide, and isolating the antibody or polypeptide.

33. The polypeptide of any one of claims 1-26, or the pharmaceutical composition of claim 27 for use as a medicament for administration to a subject, optionally wherein the polypeptide is to be administered subcutaneously.

34. Use of the polypeptide of any one of claims 1-26, or the pharmaceutical composition of claim 27, in the manufacture of a medicament for treating a disease or disorder.

35. The use of claim 34, wherein the disease or disorder is selected from an autoimmune disease or disorder, an inflammatory disease or disorder, an infection, and cancer, and/or wherein the disease or disorder in an autoantibody-mediated disease or disorder.

36. The use of claim 34 or claim 35, wherein the disease or disorder is pemphigus vulgaris, lupus nephritis, myasthenia gravis, Guillain-Barré syndrome, antibody-mediated rejection, antiphospholipid antibody syndrome, chronic inflammatory demyelinating polyneuropathy, immune complex-mediated vasculitis, glomerulitis, a channelopathy, neuromyelitis optica, autoimmune encephalitis, autoimmune Grave's disease, idiopathic thrombocytopenia purpura, autoimmune haemolytic anaemia, immune neutropenia, dilated cardiomyopathy, or serum sickness.